Trial
NCT04880564
A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Curon Biopharmaceutical (Australia) Co Pty Ltd
Collaborators
Novotech (Australia) Pty Limited
Condition
Relapsed Lymphoid Malignancies
Intervention
CN1, 0.5mg/kg and CN401, 400mg
Why stopped
Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-24